333 related articles for article (PubMed ID: 28085016)
1. Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities.
Waight JD; Gombos RB; Wilson NS
Hum Antibodies; 2017; 25(3-4):87-109. PubMed ID: 28085016
[TBL] [Abstract][Full Text] [Related]
2. Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS.
Sanmamed MF; Pastor F; Rodriguez A; Perez-Gracia JL; Rodriguez-Ruiz ME; Jure-Kunkel M; Melero I
Semin Oncol; 2015 Aug; 42(4):640-55. PubMed ID: 26320067
[TBL] [Abstract][Full Text] [Related]
3. Agonist antibodies to TNFR molecules that costimulate T and NK cells.
Melero I; Hirschhorn-Cymerman D; Morales-Kastresana A; Sanmamed MF; Wolchok JD
Clin Cancer Res; 2013 Mar; 19(5):1044-53. PubMed ID: 23460535
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity.
Kumar P; Bhattacharya P; Prabhakar BS
J Autoimmun; 2018 Dec; 95():77-99. PubMed ID: 30174217
[TBL] [Abstract][Full Text] [Related]
5. T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy.
Snell LM; Lin GH; McPherson AJ; Moraes TJ; Watts TH
Immunol Rev; 2011 Nov; 244(1):197-217. PubMed ID: 22017440
[TBL] [Abstract][Full Text] [Related]
6. OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy.
Bulliard Y; Jolicoeur R; Zhang J; Dranoff G; Wilson NS; Brogdon JL
Immunol Cell Biol; 2014 Jul; 92(6):475-80. PubMed ID: 24732076
[TBL] [Abstract][Full Text] [Related]
7. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?
Croft M
Nat Rev Immunol; 2003 Aug; 3(8):609-20. PubMed ID: 12974476
[TBL] [Abstract][Full Text] [Related]
8. Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses.
Taraban VY; Rowley TF; O'Brien L; Chan HT; Haswell LE; Green MH; Tutt AL; Glennie MJ; Al-Shamkhani A
Eur J Immunol; 2002 Dec; 32(12):3617-27. PubMed ID: 12516549
[TBL] [Abstract][Full Text] [Related]
9. TNF/TNFR family members in costimulation of T cell responses.
Watts TH
Annu Rev Immunol; 2005; 23():23-68. PubMed ID: 15771565
[TBL] [Abstract][Full Text] [Related]
10. The therapeutic potential of 4-1BB (CD137) in cancer.
Nam KO; Kang WJ; Kwon BS; Kim SJ; Lee HW
Curr Cancer Drug Targets; 2005 Aug; 5(5):357-63. PubMed ID: 16101383
[TBL] [Abstract][Full Text] [Related]
11. The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.
Moran AE; Kovacsovics-Bankowski M; Weinberg AD
Curr Opin Immunol; 2013 Apr; 25(2):230-7. PubMed ID: 23414607
[TBL] [Abstract][Full Text] [Related]
12. Tumor necrosis factor/tumor necrosis factor receptor family members that positively regulate immunity.
So T; Lee SW; Croft M
Int J Hematol; 2006 Jan; 83(1):1-11. PubMed ID: 16443545
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic vaccination with tumor cells that engage CD137.
Hellstrom KE; Hellstrom I
J Mol Med (Berl); 2003 Feb; 81(2):71-86. PubMed ID: 12601523
[TBL] [Abstract][Full Text] [Related]
14. The TNF-TNFR Family of Co-signal Molecules.
So T; Ishii N
Adv Exp Med Biol; 2019; 1189():53-84. PubMed ID: 31758531
[TBL] [Abstract][Full Text] [Related]
15. Rationale for anti-CD137 cancer immunotherapy.
Makkouk A; Chester C; Kohrt HE
Eur J Cancer; 2016 Feb; 54():112-119. PubMed ID: 26751393
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy with agonistic anti-CD137: two sides of a coin.
Sun Y; Chen JH; Fu Y
Cell Mol Immunol; 2004 Feb; 1(1):31-6. PubMed ID: 16212918
[TBL] [Abstract][Full Text] [Related]
17. Mature B cells are critical to T-cell-mediated tumor immunity induced by an agonist anti-GITR monoclonal antibody.
Zhou P; Qiu J; L'Italien L; Gu D; Hodges D; Chao CC; Schebye XM
J Immunother; 2010 Oct; 33(8):789-97. PubMed ID: 20842058
[TBL] [Abstract][Full Text] [Related]
18. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors.
Wilcox RA; Flies DB; Zhu G; Johnson AJ; Tamada K; Chapoval AI; Strome SE; Pease LR; Chen L
J Clin Invest; 2002 Mar; 109(5):651-9. PubMed ID: 11877473
[TBL] [Abstract][Full Text] [Related]
19. T cell activation with systemic agonistic antibody versus local 4-1BB ligand gene delivery combined with interleukin-12 eradicate liver metastases of breast cancer.
Martinet O; Divino CM; Zang Y; Gan Y; Mandeli J; Thung S; Pan PY; Chen SH
Gene Ther; 2002 Jun; 9(12):786-92. PubMed ID: 12040460
[TBL] [Abstract][Full Text] [Related]
20. CD27-Mediated Regulatory T Cell Depletion and Effector T Cell Costimulation Both Contribute to Antitumor Efficacy.
Wasiuk A; Testa J; Weidlick J; Sisson C; Vitale L; Widger J; Crocker A; Thomas LJ; Goldstein J; Marsh HC; Keler T; He LZ
J Immunol; 2017 Dec; 199(12):4110-4123. PubMed ID: 29109120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
